ASP9801 + pembrolizumab

ASP9801 + pembrolizumab is a **combination therapy** comprised of ASP9801, an attenuated recombinant oncolytic vaccinia virus engineered to express human interleukin-7 (IL-7) and interleukin-12 (IL-12), and pembrolizumab, a **monoclonal antibody immune-checkpoint inhibitor** targeting programmed cell death protein 1 (PD-1). ASP9801 induces local tumor destruction via virus replication, enhances tumor antigen presentation, and provokes systemic antitumor immune responses through the secretion of IL-7 and IL-12, leading to T-cell activation and cytotoxic T lymphocyte proliferation. Pembrolizumab blocks the PD-1/PD-L1 pathway, restoring and augmenting T-cell-mediated antitumor immunity. The combination aims to synergistically trigger local tumor lysis and systemic immune activation to treat advanced/metastatic solid tumors[1][3].

Other names

ASP-9801ASP9801ASP 9801pembrolizumabMK-3475MK3475MK 3475